Technical Aspects of Minimal Residual Disease Detection by Multicolor Flow Cytometry in Acute Myeloid Leukemia Patients

AUTOIMMUNE THROMBOCYTOPENIA , ,

IV Galtseva, YuO Davydova, NM Kapranov, KA Nikiforova, EN Parovichnikova

National Research Center for Hematology, 4 Novyi Zykovskii pr-d, Moscow, Russian Federation, 125167

For correspondence: Yuliya Olegovna Davydova, MD, PhD, 4 Novyi Zykovskii pr-d, Moscow, Russian Federation, 125167; Tel.: 8(495)612-62-21; e-mail: juliya89mur@yandex.ru

For citation: Galtseva IV, Davydova YuO, Kapranov NM, et al. Technical Aspects of Minimal Residual Disease Detection by Multicolor Flow Cytometry in Acute Myeloid Leukemia Patients. Clinical oncohematology. 2021;14(3):503–12. (In Russ).

DOI: 10.21320/2500-2139-2021-14-4-503-512

ABSTRACT

Detection and monitoring of minimal residual disease (MRD) are essential components of programmed therapy.They are crucial for the choice of treatment strategy and for prognostic purposes practically in all hematologic diseases. MRD is often detected by multicolor flow cytometry, the method with fairly high specificity and sensitivity. However, to identify MRD in acute myeloid leukemia patients is one of the most challenging tasks flow cytometry specialists are faced with. Cytometric data analysis requires the expert knowledge of immunophenotype of all maturing bone marrow cells. Besides, MRD analysis in acute myeloid leukemia has not been standardized while approaches suggested by different studies vary considerably. The present paper reports the experience of MRD analysis, demonstrates the gating strategy, immunophenotype description of normal non-tumor hematopoietic cells, and presents some examples of MRD assessment. Additionally, panels of monoclonal antibodies are provided, along with an evaluation of their advantages and disadvantages.

Keywords: minimal residual disease, acute myeloid leukemias, flow cytometry, gating, immunophenotyping.

Received: June 9, 2021

Accepted: September 5, 2021

Read in PDF

Статистика Plumx английский

REFERENCES

  1. Cheson BD, Bennett JM, Kopecky KJ, et al. Revised recommendations of the international working group for diagnosis, standardization of response criteria, treatment outcomes, and reporting standards for therapeutic trials in acute myeloid leukemia. J Clin Oncol. 2003;21(24):4642–9. doi: 10.1200/JCO.2003.04.036.
  2. Pui CH, Campana D. New definition of remission in childhood acute lymphoblastic leukemia. Leukemia. 2000;14(5):783–5. doi: 10.1038/sj.leu.2401780.
  3. Schuurhuis GJ, Heuser M, Freeman S, et al. Minimal/measurable residual disease in AML: a consensus document from the European LeukemiaNet MRD Working Party. Blood. 2018;131(12):1275–91. doi: 10.1182/blood-2017-09-801498.
  4. Гальцева И.В., Давыдова Ю.О., Паровичникова Е.Н. Определение минимальной измеримой остаточной болезни у взрослых больных острыми лейкозами. Гематология и трансфузиология. 2020;65(4):460–72. doi: 10.35754/0234-5730-2020-65-4-460-472.
    [Galtseva IV, Davydova YO, Parovichnikova EN. Detection of measurable residual disease in adults with acute leukaemia. Russian journal of hematology and transfusiology. 2020;65(4):460–72. doi: 10.35754/0234-5730-2020-65-4-460-472. (In Russ)]
  5. Shen Z, Gu X, Mao W, et al. Influence of pre-transplant minimal residual disease on prognosis after Allo-SCT for patients with acute lymphoblastic leukemia: Systematic review and meta-analysis. BMC Cancer. 2018;18(1):755. doi: 10.1186/s12885-018-4670-5.
  6. Leung W, Pui C-H, Coustan-Smith E, et al. Detectable minimal residual disease before hematopoietic cell transplantation is prognostic but does not preclude cure for children with very-high-risk leukemia. Blood. 2012;120(2):468–72. doi: 10.1182/blood-2012-02-409813.
  7. Norkin M, Katragadda L, Zou F, et al. Minimal residual disease by either flow cytometry or cytogenetics prior to an allogeneic hematopoietic stem cell transplant is associated with poor outcome in acute myeloid leukemia. Blood Cancer J. 2017;7(12):634. doi: 10.1038/s41408-017-0007-x.
  8. Anthias C, Dignan FL, Morilla R, et al. Pre-transplant MRD predicts outcome following reduced-intensity and myeloablative allogeneic hemopoietic SCT in AML. Bone Marrow Transplant. 2014;49(5):679–83. doi: 10.1038/bmt.2014.9.
  9. Buckley SA, Wood BL, Othus M, et al. Minimal residual disease prior to allogeneic hematopoietic cell transplantation in acute myeloid leukemia: a meta-analysis. Haematologica. 2017;102(5):865–73. doi: 10.3324/haematol.2016.159343.
  10. Wood BL. Principles of minimal residual disease detection for hematopoietic neoplasms by flow cytometry. Cytometry B Clin Cytom. 2016;90(1):47–53. doi: 10.1002/cyto.b.21239.
  11. Wood BL. Multicolor immunophenotyping: human immune system hematopoiesis. Methods Cell Biol. 2004;75:559–76. doi: 10.1016/s0091-679x(04)75023-2.
  12. Wood BL. Flow cytometric monitoring of residual disease in acute leukemia. In: Czader M, ed. Hematological Malignancies. Methods in Molecular Biology (Methods and Protocols). Vol. 999. Totowa: Humana Press; 2013. pp. 123–36. doi: 10.1007/978-1-62703-357-2_8.
  13. Лобанова Т.И., Гальцева И.В., Паровичникова Е.Н. Исследование минимальной остаточной болезни у пациентов с острыми миелоидными лейкозами методом многоцветной проточной цитофлуориметрии (обзор литературы). Онкогематология. 2018;13(1):83–102. doi: 10.17650/1818-8346-2018-13-1-83-102.
    [Lobanova TI, Galtseva IV, Parovichnikova EN. Minimal residual disease assesment in patients with acute myeloid leukemia by multicolour flow cytometry (literature review). Oncohematology. 2018;13(1):83–102. doi: 10.17650/1818-8346-2018-13-1-83-102. (In Russ)]
  14. Tien HF, Wang CH. CD7 positive hematopoietic progenitors and acute myeloid leukemia and other minimally differentiated leukemia. Leuk Lymphoma. 1998;31(1–2):93–8. doi: 10.3109/10428199809057588.
  15. Jorgensen JL, Chen SS. Monitoring of minimal residual disease in acute myeloid leukemia: methods and best applications. Clin Lymphoma Myeloma Leuk. 2011;11(Suppl 1):S49–53. doi: 10.1016/j.clml.2011.03.023.
  16. Jaso JM, Wang SA, Jorgensen JL, Lin P. Multi-color flow cytometric immunophenotyping for detection of minimal residual disease in AML: past, present and future. Bone Marrow Transplant. 2014;49(9):1129–38. doi: 10.1038/bmt.2014.99.
  17. Buldini B, Maurer-Granofszky M, Varotto E, Dworzak MN. Flow-cytometric monitoring of minimal residual disease in pediatric patients with acute myeloid leukemia: recent advances and future strategies. Front Pediatr. 2019;7:412. doi: 10.3389/fped.2019.00412.
  18. Wood BL. Acute myeloid leukemia minimal residual disease detection: the difference from normal approach. Curr Protoc Cytom. 2020;93(1):e73. doi: 10.1002/cpcy.73.
  19. Ostendorf BN, Flenner E, Florcken A, Westermann J. Phenotypic characterization of aberrant stem and progenitor cell populations in myelodysplastic syndromes. PLoS One. 2018;13(5):e0197823. doi: 10.1371/journal.pone.0197823.
  20. Goardon N, Marchi E, Atzberger A, et al. Coexistence of LMPP-like and GMP-like leukemia stem cells in acute myeloid leukemia. Cancer Cell. 2011;19(1):138–52. doi: 10.1016/j.ccr.2010.12.012.
  21. Shameli A, Dharmani-Khan P, Luider J, et al. Exploring blast composition in myelodysplastic syndromes and myelodysplastic/myeloproliferative neoplasms: CD45RA and CD371 improve diagnostic value of flow cytometry through assessment of myeloblast heterogeneity and stem cell aberrancy. Cytom Part B: Clin Cytom. 2020:1–16. doi: 10.1002/cyto.b.21983. Epub ahead of print.
  22. Bill M, van Kooten Niekerk BP, Woll SP, et al. Mapping the CLEC12A expression on myeloid progenitors in normal bone marrow; implications for understanding CLEC12A-related cancer stem cell biology. J Cell Mol Med. 2018;22(4):2311–8. doi: 10.1111/jcmm.13519.
  23. Eissens DN, Spanholtz J, van der Meer A, et al. Defining early human NK cell developmental stages in primary and secondary lymphoid tissues. PLoS One. 2012;7(2):e30930. doi: 10.1371/journal.pone.0030930.
  24. Stetler-Stevenson M, Paiva B, Stoolman L, et al. Consensus guidelines for myeloma minimal residual disease sample staining and data acquisition. Cytom Part B: Clin Cytom. 2016;90(1):26–30. doi: 10.1002/cyto.b.21249.
  25. Palmieri R, Piciocchi A, Arena V, et al. Clinical relevance of- limit of detection (LOD) – limit of quantification (LOQ) – based flow cytometry approach for measurable residual disease (MRD) assessment in acute myeloid leukemia (AML). Blood. 2020;136(Suppl 1):37–8. doi: 10.1182/blood-2020-139557.